The following is an excerpt from To read the article in full, click here.

On a conference call Tuesday, Shire聽CEO Flemming Ornskov said that the Dublin and Lexington, MA, company has discontinued development of BAX 335, an experimental gene therapy for hemophilia B.聽Prior to the merger of Baxalta and Shire, Baxalta had indicated plans to move BAX 335 into Phase 3 trials, but Shire, according to a note from Leerink Partners analyst Michael Schmidt, is looking elsewhere because of the 鈥渋nconsistent results鈥 from the therapy so far. As Schmidt pointed out, in early-stage trials, BAX 335 has led to 鈥渋nconsistent Factor IX activity levels and duration.鈥

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.